




Instance: composition-en-96431077feaab94e628cf99788cf8afd
InstanceOf: CompositionUvEpi
Title: "Composition for vazkepa Package Leaflet"
Description:  "Composition for vazkepa Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp48c0c567ed4fb75d87de0f36eb90f36d)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - vazkepa"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Vazkepa is and what it is used for </li>
<li>What you need to know before you take Vazkepa </li>
<li>How to take Vazkepa </li>
<li>Possible side effects </li>
<li>How to store Vazkepa </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What vazkepa is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What vazkepa is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Vazkepa contains the active substance icosapent ethyl, a highly purified omega-3 fatty acid from fish 
oil.  </p>
<p>Vazkepa lowers levels of triglycerides (types of fat) in the blood and it is used with a statin medicine 
(that lowers blood cholesterol) to prevent cardiovascular events, such as:</p>
<ul>
<li>heart attack </li>
<li>stroke </li>
<li>death from heart or vascular disease </li>
</ul>
<p>Vazkepa is used in adults with high blood triglycerides who already have heart disease or have 
diabetes and other conditions that put them at a higher risk of cardiovascular events. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take vazkepa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take vazkepa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Vazkepa<br />
- If you are allergic to icosapent ethyl, soya or any of the other ingredients of this medicine 
(listed in section 6). </p>
<p>Warnings and precautions<br />
Talk to your doctor or pharmacist before taking Vazkepa:</p>
<ul>
<li>If you are allergic to fish or to shellfish. </li>
<li>If you have problems with your liver. </li>
<li>If you have problems with irregular heartbeat (atrial fibrillation or flutter). </li>
<li>If you take an anticoagulant medicine (which prevents blood from clotting), medicines that 
inhibit platelets in the blood or are at risk of bleeding. </li>
</ul>
<p>If any of the above applies to you, talk to your doctor. </p>
<p>Blood tests 
During your treatment your doctor may carry out blood tests to check for any problems with your liver 
and to check how your blood is clotting. </p>
<p>Children and adolescents 
Do not give this medicine to children and young people below 18 years of age because it has not been 
studied in these people. </p>
<p>Other medicines and Vazkepa 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>If you are taking other medicines at the same time as Vazkepa that affect how your blood clots, such 
as an anticoagulant medicine, you will have blood tests during treatment. </p>
<p>Pregnancy, breast-feeding and fertility 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine. </p>
<p>Pregnancy 
Vazkepa is not recommended for use during pregnancy unless your doctor advises you to take it. </p>
<p>Breast-feeding 
Vazkepa is not recommended for use while breast-feeding as the effect on your baby is not known. 
Your doctor will help you to weigh up the benefit of treatment against any risk to your breast-feeding 
baby. </p>
<p>Fertility 
Talk with your doctor about fertility during treatment. </p>
<p>Driving and using machines 
This medicine is unlikely to affect your ability to drive or use tools or machines. </p>
<p>Vazkepa contains maltitol, sorbitol and soya lecithin  </p>
<p>Maltitol (E965 ii) 
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor 
before taking this medicine. </p>
<p>Sorbitol (E420 ii) 
This medicine contains 83 mg sorbitol in each capsule. </p>
<p>Sorbitol is a source of fructose. If your doctor has told you that you have an intolerance to some sugars 
or if you have been diagnosed with hereditary fructose intolerance (HFI), a rare genetic disorder in 
which a person cannot break down fructose, talk to your doctor before you take this medicine. </p>
<p>Soya lecithin 
This medicine contains soya lecithin. If you are allergic to soya or peanut, do not use this medicine. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take vazkepa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take vazkepa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure. Do not change your dose without talking to your doctor. </p>
<p>How to open bottle 
Push down the screw cap and turn it anticlockwise.  </p>
<p>How much to take 
The recommended dose is two capsules by mouth, twice a day, with or after a meal. </p>
<p>Swallow the capsules whole; Do not break, crush, dissolve or chew the capsules. </p>
<p>Use in elderly 
There is no need to change the dose in elderly patients. They can take the usual recommended dose. </p>
<p>If you take more Vazkepa than you should 
If you accidentally take more capsules than your doctor has prescribed, contact your doctor or 
pharmacist for advice. </p>
<p>If you forget to take Vazkepa 
If you miss a dose, take it as soon as you remember. However if you missed taking the medicine for a 
whole day, just take your next scheduled dose. Do not take a double dose to make up for a forgotten 
dose. If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>
<p>If you stop taking Vazkepa 
Do not stop taking this medicine until you have spoken with your doctor. 
If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Contact your doctor 
* if you get heart palpitations or irregular heartbeat. These could be symptoms of a serious 
condition known as atrial fibrillation. This is a common side effect (may affect up to 
1 in 10 people): 
* if you bruise easily or cannot stop bleeding. This is a very common side effect (may affect more 
than 1 in 10 people). Your risk of bleeding may increase if you are also taking an anticoagulant 
medicine.  </p>
<p>Get medical help if you get any of the following side effects. These symptoms could be due to a 
serious condition known as hypersensitivity which can happen at any time during treatment. This is 
an uncommon side effect (may affect up to 1 in 100 people) 
* difficulty breathing 
* tightening or scratching of the throat 
* swelling of the lips 
* hives (raised bumps on the skin) 
* rash and an itchy skin 
* stomach pain or cramps 
* diarrhoea 
* nausea and vomiting 
Other side effects that may occur </p>
<p>Common side effects (may affect up to 1 in 10 people): 
* swelling of your hands, arms, legs and feet<br />
* pain in muscles, bones or joints 
* gout (painful swelling in the joints because of a build up of uric acid) 
* rash 
* constipation 
* burping </p>
<p>Uncommon side effect (may affect up to 1 in 100 people) 
* bad taste in the mouth </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects, you can help provide more information on the safety 
of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store vazkepa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store vazkepa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the bottle label or blister carton after 
EXP. The expiry date refers to the last day of that month. </p>
<p>Store below 30  C. </p>
<p>Bottle: keep the bottle tightly closed in order to protect from moisture. 
Blister pack: store in the original package in order to protect from moisture. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Vazkepa contains 
* The active substance is icosapent ethyl. Each Vazkepa capsule contains 998 mg of icosapent 
ethyl. 
* The other ingredients are  * all-rac-alpha-tocopherol, gelatin, glycerol, liquid maltitol (E965 ii), liquid sorbitol (non-
crystallising) (E420 ii), purified water and soya lecithin (see section 2  Vazkepa contains 
maltitol, sorbitol and soya lecithin ). * printing ink: titanium dioxide, propylene glycol, hypromellose. </p>
<p>What Vazkepa looks like and contents of the pack </p>
<p>In this pack you will find oblong soft capsules, 25 x 10 mm, printed with  IPE  in white ink, with a 
light yellow to amber shell containing a colourless to pale yellow liquid. </p>
<p>The bottles containing 120 capsules are white 300-cc, high density polyethylene (HDPE) with a child-
resistant polypropylene heat induction sealed closure. 
Pack size of one bottle or three bottles per carton. </p>
<p>The blister packs contain 4x2 capsules in PVC/PCTFE/Al perforated unit dose blisters. </p>
<p>Marketing Authorisation Holder 
Amarin Pharmaceuticals Ireland Limited<br />
88 Harcourt Street 
Dublin 2, D02DKIreland </p>
<p>Manufacturer 
MIAS Pharma Limited 
Suite 1, Stafford House, Strand Road 
Portmarnock,<br />
D13 WCIreland </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Amarin Pharmaceuticals Ireland Limited 
T l/Tel: 0800-75AmarinConnect@amarincorp.eu </p>
<p>Lietuva 
Amarin Pharmaceuticals Ireland Limited 
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Amarin Pharmaceuticals Ireland Limited 
Te .: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Luxembourg/Luxemburg 
Amarin Pharmaceuticals Ireland Limited 
T l/Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>esk  republika 
Amarin Pharmaceuticals Ireland Limited 
Tlf: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Magyarorsz g 
Amarin Pharmaceuticals Ireland Limited 
Tel.: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Danmark 
Amarin Pharmaceuticals Ireland Limited 
Tlf: +46-84-4685AmarinConnect@amarincorp.eu </p>
<p>Malta 
Amarin Pharmaceuticals Ireland Limited 
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Deutschland 
Amarin Germany GmbH 
Tel: 0800-0008AmarinConnect@amarincorp.eu </p>
<p>Nederland 
Amarin Pharmaceuticals Ireland Limited 
Tel: 0800-0228AmarinConnect@amarincorp.eu </p>
<p>Eesti 
Amarin Pharmaceuticals Ireland Limited 
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Norge 
Amarin Pharmaceuticals Ireland Limited 
Tlf: +46 84 468 5AmarinConnect@amarincorp.eu </p>
<p>Amarin Pharmaceuticals Ireland Limited<br />
 : +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>sterreich 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: 0800-281AmarinConnect@amarincorp.eu </p>
<p>Espa a 
Amarin Pharmaceuticals Ireland Limited<br />
Polska 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: 900806AmarinConnect@amarincorp.eu </p>
<p>Tel.: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>France 
Amarin Pharmaceuticals Ireland Limited<br />
T l: 0800-991AmarinConnect@amarincorp.eu </p>
<p>Portugal 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Hrvatska 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Rom nia 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Ireland 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Slovenija 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>sland 
Amarin Pharmaceuticals Ireland Limited<br />
S mi: +46-84-4685AmarinConnect@amarincorp.eu </p>
<p>Slovensk  republika 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Italia 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Suomi/Finland 
Amarin Pharmaceuticals Ireland Limited<br />
Puh/Tel: +46-84-4685AmarinConnect@amarincorp.eu </p>
<p>Amarin Pharmaceuticals Ireland Limited<br />
 : +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Sverige 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: +46-84-4685AmarinConnect@amarincorp.eu </p>
<p>Latvija 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>United Kingdom (Northern Ireland) 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: 0800-0478AmarinConnect@amarincorp.eu </p>
<p>This leaflet was last revised in . </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-96431077feaab94e628cf99788cf8afd
InstanceOf: CompositionUvEpi
Title: "Composition for vazkepa Package Leaflet"
Description:  "Composition for vazkepa Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp48c0c567ed4fb75d87de0f36eb90f36d)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - vazkepa"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse<br />
2. Det skal du vide, før du begynder at tage Vazkepa 
3. Sådan skal du tage Vazkepa 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What vazkepa is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What vazkepa is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Vazkepa indeholder det aktive stof icosapentethyl, som er en omega-3 fedtsyre kraftigt oprenset fra 
fiskeolie.  </p>
<p>Vazkepa sænker indholdet af triglycerider (typer af fedtstoffer) i blodet, og det anvendes sammen med 
et statin (kolesterolsænkende lægemiddel) til at forebygge hjerte-karhændelser som f.eks.:</p>
<ul>
<li>hjerteanfald </li>
<li>slagtilfælde </li>
<li>dødsfald pga. hjertekarsygdom </li>
</ul>
<p>Vazkepa anvendes til voksne med højt indhold af triglycerider i blodet, som i forvejen har en 
hjertesygdom eller diabetes og andre sygdomme, der gør, at de har en øget risiko for hjertekar-tilfælde. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take vazkepa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take vazkepa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Vazkepa 
- hvis du er allergisk over for icosapentethyl, soja eller et af de øvrige indholdsstoffer i dette 
lægemiddel (angivet i punkt 6). </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før du tager Vazkepa:</p>
<ul>
<li>Hvis du er allergisk over for fisk eller skaldyr. </li>
<li>Hvis du har problemer med leveren. </li>
<li>Hvis du har problemer med uregelmæssig hjerterytme (puls) (atrieflimren eller atrieflagren). </li>
<li>Hvis du tager blodfortyndende medicin (antikoagulantia - forhindrer blodet i at størkne), medicin 
som hæmmer blodplader eller har risiko for blødning </li>
</ul>
<p>Kontakt lægen, hvis noget af ovenstående gælder for dig. </p>
<p>Blodprøver 
I løbet af din behandling vil lægen muligvis tage blodprøver for at kontrollere, om der er problemer 
med din lever og for at kontrollere, hvordan dit blod størkner. </p>
<p>Børn og unge<br />
Børn og unge under 18 år må ikke få dette lægemiddel, da det ikke er blevet undersøgt hos disse 
personer. </p>
<p>Brug af anden medicin sammen med Vazkepa 
Fortæl det altid til lægen eller apotekspersonalet, hvis du tager anden medicin, for nylig har taget 
anden medicin eller planlægger at tage anden medicin. </p>
<p>Hvis du tager andre lægemidler, der påvirker, hvordan dit blod størkner, som f.eks. blodfortyndende 
medicin (antikoagulantia), samtidigt med Vazkepa, vil du få taget blodprøver i løbet af behandlingen. </p>
<p>Graviditet, amning og frugtbarhed 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge eller apotekspersonalet til råds, før du tager dette lægemiddel. </p>
<p>Graviditet 
Du bør ikke tage Vazkepa, hvis du er gravid, medmindre din læge har anbefalet det. </p>
<p>Amning 
Du bør ikke tage Vazkepa, mens du ammer, da virkningen på dit barn ikke er kendt. Din læge vil 
sammen med dig afveje fordelen ved behandlingen imod en eventuel risiko for dit ammede barn. </p>
<p>Frugtbarhed 
Tal med din læge om frugtbarhed under behandlingen. </p>
<p>Trafik- og arbejdssikkerhed 
Det er ikke sandsynligt, at dette lægemiddel påvirker evnen til at føre motorkøretøj eller betjene 
værktøj eller maskiner. </p>
<p>Vazkepa indeholder maltitol, sorbitol og sojalecithin </p>
<p>Maltitol (E965 ii) 
Kontakt lægen, før du tager dette lægemiddel, hvis lægen har fortalt dig, at du ikke tåler visse 
sukkerarter. </p>
<p>Sorbitol (E420 ii) 
Dette lægemiddel indeholder 83 mg sorbitol pr. kapsel. </p>
<p>Sorbitol er en kilde til fructose. Hvis din læge har fortalt dig, at du har intolerance over for nogle 
sukkerarter, eller hvis du er blevet diagnosticeret med arvelig fructoseintolerans (HFI), en sjælden 
genetisk lidelse, hvor en person ikke kan nedbryde fructose, skal du tale med din læge, før du tager 
dette lægemiddel. </p>
<p>Sojalecithin 
Dette lægemiddel indeholder sojalecithin. Du må ikke bruge Vazkepa, hvis du er overfølsom over for 
soja eller jordnødder. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take vazkepa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take vazkepa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen eller 
apotekspersonalet. Du må ikke ændre din dosis uden at tale med lægen. </p>
<p>Sådan åbnes beholderen 
Pres skruelåget ned, og drej det mod uret.  </p>
<p>Så meget skal du tage 
Den anbefalede dosis er to kapsler to gange dagligt taget gennem munden sammen med eller efter et 
måltid. </p>
<p>Slug kapslerne hele. Du må ikke dele, knuse, opløse eller tygge kapslerne. </p>
<p>Brug til ældre 
Det er ikke nødvendigt at ændre dosis til ældre patienter. De kan tage den normale anbefalede dosis. </p>
<p>Hvis du har taget for meget Vazkepa 
Hvis du ved et uheld tager flere kapsler end lægen har ordineret, skal du kontakte lægen eller 
apotekspersonalet for rådgivning. </p>
<p>Hvis du har glemt at tage Vazkepa 
Hvis du har glemt en dosis, skal du tage den så snart du kommer i tanke om det. Hvis du imidlertid har 
glemt at tage medicinen en hel dag, skal du blot tage den næste dosis som planlagt. Du må du ikke 
tage en dobbeltdosis som erstatning for den glemte dosis. Spørg lægen eller apotekspersonalet, hvis 
der er noget, du er i tvivl om. </p>
<p>Hvis du holder op med at tage Vazkepa 
Du må ikke stoppe med at tage denne medicin uden at have talt med lægen om det. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Kontakt din læge </p>
<ul>
<li>
<p>hvis du får hjertebanken eller uregelmæssig puls (hjerterytme). Det kan være symptomer på 
en alvorlig tilstand ved navn atrieflimren. Det er en almindelig bivirkning (kan forekomme 
hos op til 1 ud af 10 personer): </p>
</li>
<li>
<p>hvis du let får blå mærker eller ikke kan holde op med at bløde. Det er en meget almindelig 
bivirkning (kan forekomme hos flere end 1 ud af 10 personer). Det kan øge din risiko for 
blødning, hvis du også tager blodfortyndende medicin.  </p>
</li>
</ul>
<p>Søg lægehjælp, hvis du får en eller flere af følgende bivirkninger. Disse symptomer kan skyldes en 
alvorlig tilstand ved navn overfølsomhed, som kan opstå på et hvilket som helst tidspunkt under 
behandlingen. Det er en ikke almindelig bivirkning (kan forekomme hos op til 1 ud af 100 personer) 
• vejrtrækningsbesvær 
• sammentrækning af svælget eller kradsen i svælget 
• hævede læber 
• nældefeber (hævede pletter på huden) 
• udslæt og kløende hud 
• mavesmerter eller mavekramper 
• diarré 
• kvalme og opkastning </p>
<p>Andre bivirkninger </p>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 personer): </p>
<ul>
<li>
<p>hævede hænder, arme, ben og fødder  </p>
</li>
<li>
<p>smerter i muskler, knogler eller led  </p>
</li>
<li>
<p>urinsyregigt (smertefuld hævelse af led på grund af ophobet urinsyre) </p>
</li>
<li>
<p>udslæt </p>
</li>
<li>
<p>forstoppelse </p>
</li>
<li>
<p>bøvsen </p>
</li>
</ul>
<p>Ikke almindelig bivirkning (kan forekomme hos op til 1 ud af 100 personer) </p>
<ul>
<li>dårlig smag i munden </li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store vazkepa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store vazkepa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på etiketten på beholderen eller æsken til blisteren 
efter EXP. Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Opbevares ved temperaturer under 30 °C. </p>
<p>Beholder: Hold beholderen tæt tillukket for at beskytte mod fugt. 
Blister: Opbevares i original emballage for at beskytte mod fugt. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Vazkepa indeholder:</p>
<ul>
<li>Aktivt stof: icosapentethyl. En Vazkepa kapsel indeholder 998 mg icosapentethyl. </li>
<li>Øvrige indholdsstoffer: * all-rac-alpha-tocopherol, gelatine, glycerol, flydende maltitol (E965 ii), flydende sorbitol 
(ikke-krystalliserende) (E420 ii), renset vand og sojalecithin (se punkt 2 “Vazkepa 
indeholder maltitol, sorbitol og sojalecithin"). * prægeblæk: titandioxid, propylenglycol, hypromellose. </li>
</ul>
<p>Udseende og pakningsstørrelser </p>
<p>Denne pakning indeholder aflange, bløde kapsler, 25 mm x 10 mm præget med ‘IPE’ med hvidt blæk 
med en lysegul til ravfarvet kapselskal indeholdende en farveløs til bleggul væske. </p>
<p>Beholderen med 120 kapsler er en hvid 300-cc, HDPE (High-density polyethylen)- beholder med 
børnesikret polypropylenlåg med varmeinduceret forsegling. 
Pakningsstørrelse med én beholder eller tre beholdere pr. æske. </p>
<p>Blisterpakningen indeholder 4x2 kapsler i PVC/PCTFE/Al perforerede enkeltdosisblistere. </p>
<p>Indehaver af markedsføringstilladelsen<br />
Amarin Pharmaceuticals Ireland Limited<br />
88 Harcourt Street 
Dublin 2, D02DKIrland </p>
<p>Fremstiller 
MIAS Pharma Limited 
Suite 1, Stafford House, Strand Road 
Portmarnock 
D13 WCIrland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Amarin Pharmaceuticals Ireland Limited 
Tél/Tel: 0800-75AmarinConnect@amarincorp.eu </p>
<p>Lietuva 
Amarin Pharmaceuticals Ireland Limited 
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>България 
Amarin Pharmaceuticals Ireland Limited 
Teл.: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Luxembourg/Luxemburg 
Amarin Pharmaceuticals Ireland Limited 
Tél/Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Česká republika 
Amarin Pharmaceuticals Ireland Limited 
Tlf: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Magyarország 
Amarin Pharmaceuticals Ireland Limited 
Tel.: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Danmark 
Amarin Pharmaceuticals Ireland Limited 
Tlf: +46-84-4685AmarinConnect@amarincorp.eu </p>
<p>Malta 
Amarin Pharmaceuticals Ireland Limited 
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Deutschland 
Amarin Germany GmbH 
Tel: 0800-0008AmarinConnect@amarincorp.eu </p>
<p>Nederland 
Amarin Pharmaceuticals Ireland Limited 
Tel: 0800-0228AmarinConnect@amarincorp.eu </p>
<p>Eesti 
Amarin Pharmaceuticals Ireland Limited 
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Norge 
Amarin Pharmaceuticals Ireland Limited 
Tlf: +46 84 468 5AmarinConnect@amarincorp.eu </p>
<p>Ελλάδα 
Amarin Pharmaceuticals Ireland Limited<br />
Österreich 
Amarin Pharmaceuticals Ireland Limited<br />
Τηλ: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Tel: 0800-281AmarinConnect@amarincorp.eu </p>
<p>España 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: 900806AmarinConnect@amarincorp.eu </p>
<p>Polska 
Amarin Pharmaceuticals Ireland Limited<br />
Tel.: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>France 
Amarin Pharmaceuticals Ireland Limited<br />
Tél: 0800-991AmarinConnect@amarincorp.eu </p>
<p>Portugal 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Hrvatska 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>România 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Ireland 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Slovenija 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Ísland 
Amarin Pharmaceuticals Ireland Limited<br />
Sími: +46-84-4685AmarinConnect@amarincorp.eu </p>
<p>Slovenská republika 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Italia 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Suomi/Finland 
Amarin Pharmaceuticals Ireland Limited<br />
Puh/Tel: +46-84-4685AmarinConnect@amarincorp.eu </p>
<p>Κύπρος 
Amarin Pharmaceuticals Ireland Limited<br />
Τηλ: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Sverige 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: +46-84-4685AmarinConnect@amarincorp.eu </p>
<p>Latvija 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>United Kingdom (Northern Ireland) 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: 0800-0478AmarinConnect@amarincorp.eu </p>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu  </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-96431077feaab94e628cf99788cf8afd
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for vazkepa Package Leaflet for language en"
Description: "ePI document Bundle for vazkepa Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-96431077feaab94e628cf99788cf8afd"
* entry[0].resource = composition-en-96431077feaab94e628cf99788cf8afd

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp96431077feaab94e628cf99788cf8afd"
* entry[=].resource = mp96431077feaab94e628cf99788cf8afd
                            
                    
Instance: bundlepackageleaflet-da-96431077feaab94e628cf99788cf8afd
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for vazkepa Package Leaflet for language da"
Description: "ePI document Bundle for vazkepa Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-96431077feaab94e628cf99788cf8afd"
* entry[0].resource = composition-da-96431077feaab94e628cf99788cf8afd

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp96431077feaab94e628cf99788cf8afd"
* entry[=].resource = mp96431077feaab94e628cf99788cf8afd
                            
                    



Instance: mp96431077feaab94e628cf99788cf8afd
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Vazkepa 998 mg soft capsules"
Description: "Vazkepa 998 mg soft capsules"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/20/1524/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Vazkepa 998 mg soft capsules"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 96431077feaab94e628cf99788cf8afdListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "vazkepa"

* status = #current
* mode = #working

* title = "List of all ePIs associated with vazkepa"

* subject = Reference(mp48c0c567ed4fb75d87de0f36eb90f36d)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#vazkepa "vazkepa"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-96431077feaab94e628cf99788cf8afd) // vazkepa en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-96431077feaab94e628cf99788cf8afd) // vazkepa da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-96431077feaab94e628cf99788cf8afd
InstanceOf: List

* insert 96431077feaab94e628cf99788cf8afdListRuleset
    